Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

This study aims to evaluate the safety of avasopasem in combination with CDK 4/6 inhibitor and hormonal therapy in women with metastatic hormone receptor positive breast cancer, and to see if the addition of avasopasem improves the effectiveness of a CDK 4/6 inhibitor and hormonal therapy.

NCT Number	NCT07137871
Lead Sponsor	The University of Texas Health Science Center at San Antonio
Conditions	Breast Cancer Metastatic
Enrollment	35 participants
Start Date	2025-10-02
Primary Completion	2027-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2025-10-31